Biotron expands HCV trial
Thursday, 14 August, 2008
Biotron [ASX: BIT] has expanded its Phase Ib/IIa clinical trial of its BIT225 hepatitis C treatment in an effort to maximise recruitment rates.
Testing will now be conducted at a Brisbane site in addition to the planned trial at a site in NSW.
The trial will be a placebo-controlled, randomised and multi-dose study examining the safety, pharmacokinetics and antiviral activity of the treatment.
The trial should be completed by the end of the year.
BIT225 targets the p7 protein of HCV, and has shown promising results in surrogate models of HCV infection.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
